These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38865344)

  • 1. Evaluation of transmission-blocking potential of PvPSOP25 using transgenic murine malaria parasite and clinical isolates.
    Zhang B; Feng H; Zhao Y; Zhang D; Yu X; Li Y; Zeng Y; Thongpoon S; Roobsoong W; Wu Y; Liu F; Sattabongkot J; Min H; Cui L; Cao Y
    PLoS Negl Trop Dis; 2024 Jun; 18(6):e0012231. PubMed ID: 38865344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate.
    Zheng W; Liu F; He Y; Liu Q; Humphreys GB; Tsuboi T; Fan Q; Luo E; Cao Y; Cui L
    Parasit Vectors; 2017 Jan; 10(1):8. PubMed ID: 28057055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of transmission-blocking potential of Pv22 using clinical Plasmodium vivax infections and transgenic Plasmodium berghei.
    Bai J; Liu F; Yang F; Zhao Y; Jia X; Thongpoon S; Roobsoog W; Sattabongkot J; Zheng L; Cui Z; Zheng W; Cui L; Cao Y
    Vaccine; 2023 Jan; 41(2):555-563. PubMed ID: 36503858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of two Plasmodium vivax sexual stage antigens as transmission-blocking vaccine candidates.
    Zhang Y; Liu F; Zhao Y; Yang F; Bai J; Jia X; Roobsoong W; Sattabongkot J; Cui L; Cao Y; Luo E; Wang M
    Parasit Vectors; 2021 Aug; 14(1):407. PubMed ID: 34399829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization.
    Tachibana M; Suwanabun N; Kaneko O; Iriko H; Otsuki H; Sattabongkot J; Kaneko A; Herrera S; Torii M; Tsuboi T
    Vaccine; 2015 Apr; 33(16):1901-8. PubMed ID: 25765968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.
    Ramjanee S; Robertson JS; Franke-Fayard B; Sinha R; Waters AP; Janse CJ; Wu Y; Blagborough AM; Saul A; Sinden RE
    Vaccine; 2007 Jan; 25(5):886-94. PubMed ID: 17049690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional Conservation of P48/45 Proteins in the Transmission Stages of
    Cao Y; Hart RJ; Bansal GP; Kumar N
    mBio; 2018 Sep; 9(5):. PubMed ID: 30181253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a Plasmodium berghei sexual stage antigen PbPH as a new candidate for malaria transmission-blocking vaccine.
    Kou X; Zheng W; Du F; Liu F; Wang M; Fan Q; Cui L; Luo E; Cao Y
    Parasit Vectors; 2016 Apr; 9():190. PubMed ID: 27038925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A conserved malaria parasite antigen Pb22 plays a critical role in male gametogenesis in Plasmodium berghei.
    Liu F; Yang F; Wang Y; Hong M; Zheng W; Min H; Li D; Jin Y; Tsuboi T; Cui L; Cao Y
    Cell Microbiol; 2021 Mar; 23(3):e13294. PubMed ID: 33222390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Ex Vivo Assay to Evaluate Functional Effectiveness of Plasmodium vivax Transmission-Blocking Vaccine Using Pvs25 Transgenic Plasmodium berghei.
    Cao Y; Hayashi CTH; Kumar N
    J Infect Dis; 2024 Jun; 229(6):1894-1903. PubMed ID: 38408353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Plasmodium berghei sexual stage antigen PSOP12 induces anti-malarial transmission blocking immunity both in vivo and in vitro.
    Sala KA; Nishiura H; Upton LM; Zakutansky SE; Delves MJ; Iyori M; Mizutani M; Sinden RE; Yoshida S; Blagborough AM
    Vaccine; 2015 Jan; 33(3):437-45. PubMed ID: 25454088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Plasmodium berghei Pbg37 as Both a Pre- and Postfertilization Antigen with Transmission-Blocking Potential.
    Liu F; Li L; Zheng W; He Y; Wang Y; Zhu X; Tsuboi T; Cui L; Wang M; Cao Y
    Infect Immun; 2018 Aug; 86(8):. PubMed ID: 29866905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of two sexual-stage antigens as bivalent transmission-blocking vaccines in rodent malaria.
    Yang F; Liu F; Yu X; Zheng W; Wu Y; Qiu Y; Jin Y; Cui L; Cao Y
    Parasit Vectors; 2021 May; 14(1):241. PubMed ID: 33962671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites.
    Mizutani M; Iyori M; Blagborough AM; Fukumoto S; Funatsu T; Sinden RE; Yoshida S
    Infect Immun; 2014 Oct; 82(10):4348-57. PubMed ID: 25092912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
    Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
    Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites.
    Bauza K; Malinauskas T; Pfander C; Anar B; Jones EY; Billker O; Hill AV; Reyes-Sandoval A
    Infect Immun; 2014 Mar; 82(3):1277-86. PubMed ID: 24379295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of three ookinete-specific genes and evaluation of their transmission-blocking potentials in Plasmodium berghei.
    Zheng W; Kou X; Du Y; Liu F; Yu C; Tsuboi T; Fan Q; Luo E; Cao Y; Cui L
    Vaccine; 2016 May; 34(23):2570-8. PubMed ID: 27083421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy.
    Kongkasuriyachai D; Bartels-Andrews L; Stowers A; Collins WE; Sullivan J; Sattabongkot J; Torii M; Tsuboi T; Kumar N
    Vaccine; 2004 Aug; 22(23-24):3205-13. PubMed ID: 15297075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate.
    Tachibana M; Sato C; Otsuki H; Sattabongkot J; Kaneko O; Torii M; Tsuboi T
    Vaccine; 2012 Feb; 30(10):1807-12. PubMed ID: 22245309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Plasmodium berghei transgenic parasite expressing the full-length Plasmodium vivax circumsporozoite VK247 protein for testing vaccine efficacy in a murine model.
    Mizutani M; Fukumoto S; Soubeiga AP; Soga A; Iyori M; Yoshida S
    Malar J; 2016 Apr; 15(1):251. PubMed ID: 27129682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.